USE OF WARFARIN IN PEDIATRICS: CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS

Bruna Bergmann Santos1, Isabela Heineck1, Giovanna Webster Negretto2

  • 1Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil.

Insights

Warfarin anticoagulation in children is complex, with central venous catheters being a major risk factor for thrombotic events. Infants and those on total parenteral nutrition require higher doses and longer monitoring for effective warfarin therapy.

Area of Science:

  • Pediatric Pharmacology
  • Hematology
  • Clinical Pharmacy

Background:

  • Oral anticoagulation with warfarin is crucial for preventing thrombotic events in children.
  • Understanding factors influencing warfarin efficacy and safety in pediatric populations is essential for optimizing treatment.

Purpose of the Study:

  • To analyze pediatric responses to warfarin, focusing on age, clinical status, administration route, and total parenteral nutrition (TPN).
  • To identify risk factors associated with thrombotic events (TE) in children receiving warfarin therapy.

Main Methods:

  • A retrospective descriptive study of pediatric patients (≤18 years) treated with warfarin at a university hospital.
  • Data collection from medical records, analyzing risk factors for TE, time to therapeutic International Normalized Ratio (INR), and adverse events.

Main Results:

  • Central venous catheter use was the primary risk factor for TE (89.6%).
  • Patients with short bowel syndrome and TPN required higher warfarin doses for target INR.
  • Infants (≤1 year) needed longer periods and higher doses for anticoagulation compared to older children.

Conclusions:

  • Pediatric warfarin therapy is complex, necessitating standardized protocols.
  • Development of clinical practice guidelines is recommended to manage anticoagulation effectively in children.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371